Get started
Work

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples

Year: 2019
Type: article
DOI: 10.1016/j.jtho.2019.07.016
Authors: Deepa Rangachari, Ciric To, Jason E. Shpilsky, Paul A. VanderLaan, Susumu S. Kobayashi, Mierzhati Mushajiang, Christie J. Lau, Cloud P. Paweletz, Geoffrey R. Oxnard, Pasi A. Jänne, Daniel B. Costa
Language: English
Field: Medicine
Open Access status: bronze
Funders: Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Novartis, Ariad Pharmaceuticals, Taiho Pharmaceutical, Novocure, Clovis Oncology, Daiichi-Sankyo, AstraZeneca Korea, Astellas Pharma, National Institutes of Health, Genentech, Merck Sharp and Dohme, Chugai Pharmaceutical, Takeda Oncology, Loxo Oncology, Foundation Medicine, Japan Society for the Promotion of Science, National Cancer Institute
Awards: Identification of the mechanisms underlying tumorigenesis by oncogenic tyrosine kinases, G5365048700, G601477287, G7454747284, G87415391, G9000094414, G9000117267
OpenAlex ID: W2964827678
FWCI: 7.106
Cites: 15
Cited by: 96
Related to: 10